Keywords: france, sanofi-synthelabo, continues, outperform, competitors, reports, its
France's Sanofi-Synthelabo continues to outperform competitors
Article | 26 October 2001
Sanofi-Synthelabo of France reports that its nine-month 2001 salesreached 4.81 billion euros ($4.29 billion), an increase of 16.1% on a comparable basis and 10.8% on ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- Elan makes "transformational" acquisitions and a divestment
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- CIS countries prepare for the introduction of drug reimbursement schemes
- Greek research-based drugmaker group AIFD challenges generics assumptions in Draft Patent Law
